CHMP issues guidelines on treating infants in a H1N1 pandemic
This article was originally published in Scrip
The EU's CHMP made a series of recommendations on the treatment and prophylaxis of influenza A, H1N1, infection in children aged less than one year during a pandemic at its May meeting.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.